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AbstrACt
background Interleukin-15 (IL-15) promotes growth and 
activation of cytotoxic CD8+ T and natural killer (NK) cells. 
Bioactive IL-15 is produced in the body as a heterodimeric 
cytokine, comprising the IL-15 and IL-15 receptor alpha 
chains (hetIL-15). Several preclinical models support the 
antitumor activity of hetIL-15 promoting its application in 
clinical trials.
Methods The antitumor activity of hetIL-15 produced 
from mammalian cells was tested in mouse tumor 
models (MC38 colon carcinoma and TC-1 epithelial 
carcinoma). The functional diversity of the immune 
infiltrate and the cytokine/chemokine network within 
the tumor was evaluated by flow cytometry, multicolor 
immunohistochemistry (IHC), gene expression profiling 
by Nanostring Technologies, and protein analysis by 
electrochemiluminescence and ELISA assays.
results hetIL-15 treatment resulted in delayed primary 
tumor growth. Increased NK and CD8+ T cell tumoral 
infiltration with an increased CD8+/Treg ratio were found 
by flow cytometry and IHC in hetIL-15 treated animals. 
Intratumoral NK and CD8+ T cells showed activation 
features with enhanced interferon-γ (IFN-γ) production, 
proliferation (Ki67+), cytotoxic potential (Granzyme B+) and 
expression of the survival factor Bcl-2. Transcriptomics 
and proteomics analyses revealed complex effects 
on the tumor microenvironment triggered by hetIL-15 
therapy, including increased levels of IFN-γ and XCL1 
with intratumoral accumulation of XCR1+IRF8+CD103+ 
conventional type 1 dendritic cells (cDC1). Concomitantly, 
the production of the chemokines CXCL9 and CXCL10 
by tumor- localized myeloid cells, including cDC1, was 
boosted by hetIL-15 in an IFN-γ-dependent manner. An 
increased frequency of circulating CXCR3+ NK and CD8+ T 
cells was found, suggesting their ability to migrate toward 
the tumors following the CXCL9 and CXCL10 chemokine 
gradient.
Conclusions Our results show that hetIL-15 
administration enhances T cell entry into tumors, 
increasing the success rate of immunotherapy 
interventions. Our study further supports the incorporation 
of hetIL-15 in tumor immunotherapy approaches to 
promote the development of antitumor responses by 
favoring effector over regulatory cells and by promoting 
lymphocyte and DC localization into tumors through the 
modification of the tumor chemokine and cytokine milieu.
bACkground
Immunotherapy has emerged as a valuable 
strategy for the treatment of several type of 
cancers.1 2 The clinical use of cytokines, anti-
bodies targeting checkpoint inhibitors and 
adoptive cell transfer is increasing, although 
only a subset of patients benefits from 
these approaches. The presence of tumor- 
infiltrating effector T cells is considered 
a favorable prognostic indicator in many 
cancer types.3 In colorectal cancer, the infil-
tration of cytotoxic memory T cells within the 
tumor center and invasive margin represents 
an important predictor of survival.4–6 During 
programmed cell death protein-1 blockade 
treatment, higher numbers of CD8+ T cells 
are found within the tumor of responder 
patients.7 Several studies suggest that the 
ratio of CD8+/Treg cells within the tumor 
is an important predictor of cancer immu-
notherapy success.8 The presence of intra-
tumoral conventional type 1 dendritic cells 
(cDC1) has also been positively associated 
with patient survival in multiple cancers.9 10 
In preclinical models, abundance of cDC1 
within the tumor microenvironment is asso-
ciated with tumor regression and considered 
critical for the success of T cell- based immu-
notherapies.11–13 cDC1 development requires 
expression of the transcription factors Inter-
feron regulatory factor 8 (IRF8) and Basic 
leucin zipper transcriptional factor ATF- like 
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3 (Batf3)14; they can be identified by surface expres-
sion of CD11c, the X- C Motif Chemokine Receptor 1 
(XCR1)15 16 and the C- type lectin receptor DNGR-1.17 
In non- lymphoid tissues, including tumors, cDC1 cells 
also express integrinαE (CD103), whereas expression 
of CD11b is low.10 12 18 The recruitment and retention 
of cDC1s within the tumor are regulated by chemok-
ines released by cancer cells, stroma and intratumoral 
lymphocytes.11 19 The antitumoral activity of cDC1 relates 
to their ability to cross- present tumor antigens taken 
up within the tumor microenvironment, and to initiate 
primary T cell responses in the tumor- draining lymph 
nodes,12 18 20 enhancing local cytotoxic lymphocyte 
function.10 21 Additionally, cDC1 may contribute to the 
recruitment of effector T cells by releasing Chemokine 
(C- X- C motif) ligand 9 (CXCL9) and Chemokine (C- X- C 
motif) ligand 10 (CXCL10),13 22 23 establishing a favor-
able chemokine gradient within the tumor. Analyses of 
the tumor cytokine landscape have shown that interfer-
on-γ (IFN-γ)24 and interleukin-15 (IL-15)25–27 signatures 
are also associated with beneficial antitumor responses.
IL-15 is of great interest to the cancer immunotherapy 
field due to its ability to promote survival and stimulate 
several leucocyte subsets including natural killer (NK), 
CD8+ and γδ T cells28 that possess antitumor properties. 
In phase I clinical trials, Escherichia coli- derived single- 
chain IL-15 was shown to expand NK and CD8+ T cells, 
but the short plasma half- life29 and immunogenicity in 
humans29 30 may limit the therapeutic use of this mole-
cule. IL-15 expression in vivo requires the intracel-
lular binding of IL-15 to IL-15 receptor α (IL- 15Rα) in 
producer cells.31–34 Indeed, we have reported that bioac-
tive IL-15 in vivo comprises a complex of the IL-15 chain 
with the IL- 15Rα chain, which together form the IL-15 
heterodimer (named hetIL-15).35 36 The two chains, IL-15 
and IL- 15Rα, are produced coordinately in the same cell 
and associate rapidly in the endoplasmic reticulum36 37 
due to their high binding affinity (kd ~10
-11). hetIL-15 
is then transported to the cell surface and, on proteo-
lytic cleavage of IL- 15Rα, released as bioactive soluble 
heterodimeric molecule.35 36 38–40 hetIL-15 produced 
from human HEK293 cells is well tolerated and bioactive 
in both mice41 and rhesus macaques.42 43 Therapeutic 
efficacy of hetIL-15 and molecules composed of parts of 
IL-15 and IL- 15Rα has been shown in preclinical cancer 
models,40 44–48 and several molecules similar to hetIL-15 
are currently being evaluated in cancer immunotherapy 
clinical trials (NCT02452268 and49 50). We have shown 
in the B16 melanoma model that hetIL-15 enhances the 
survival, proliferation and antitumor effects of adoptively 
transferred Pmel-1 cells without the need for lymphode-
pletion preconditioning, resulting in improved tumor 
control and survival.47 Overall, hetIL-15 administration 
is associated with increased proliferation of effector 
memory T lymphocytes and NK cells expressing the cyto-
toxic serine protease Granzyme B (GzmB).47 However, 
the mechanism(s) underlying promotion of antitumor 
responses by IL-15 is still not completely understood.
The objectives of this study were to explore how hetIL-15 
promotes lymphocyte entry into the tumor and to charac-
terize the interactions between tumor- infiltrating lympho-
cytes (TILs) and other cell types through the analysis of 
cytokines and chemokines affected by hetIL-15 therapy.
Methods
Mice
C57BL/6 mice were obtained from Charles River Labora-
tory and Envigo (Frederick, MD). IL-15 knock out (KO) 
mice were purchased from Taconic. IFN-γ KO were kindly 
provided by the Cancer Inflammation Program, National 
Cancer Institute.
Mouse tumor models and hetIL-15 immunotherapy
Murine carcinoma-38 (MC38) colon carcinoma and 
Tissue culture-1 (TC-1) lung epithelial cell- derived carci-
noma cells were maintained in Dulbecco's Modified 
Eagle Medium (DMEM) supplemented with 10% heat- 
inactivated fetal bovine serum (Sigma), penicillin/strep-
tomycin, essential amino acids and 4-(2- hydroxyethyl)-1
- piperazineethanesulfonic acid (HEPES). Animals aged 
6–8 weeks received 1–2×105 tumor cells by subcutaneous 
(SC) injection in the flank. Five days after inoculation of 
tumor cells, tumor- bearing mice were randomized into 
two groups, untreated and hetIL-15 treated. hetIL-15 was 
purified from HEK293 cells (Admune Therapeutic LLC/
Novartis). For hetIL-15 treatment, mice received intra-
peritoneal (IP) injection of 3 µg (molar mass of IL-15) 
of hetIL-1541 51 three times/week for a total of 4–8 injec-
tions. Tumor area (length x width) was measured every 
2–3 days in a blinded fashion. To block protein secretion 
from tumor cells in vivo, 100 µg brefeldin (Sigma) at a 
concentration of 10 mg/mL were delivered intratumor-
ally (IT), 30 min before sacrifice and tumor excision, in 
some experiments.
Preparation of single cell suspension and flow cytometry
Excised tumors were cut into small pieces and digested 
using the Tumor Dissociation Kit (130-096-730, Miltenyi 
Biotec), as per manufacturer’s instructions. In some 
experiments, CD8+ T cells were isolated from tumor cell 
suspensions using Dynabeads FlowComp Mouse CD8 Kit 
(ThermoFisher Scientific), as per manufacturer’s instruc-
tions. Spleens were dissociated using a 100 µm cell strainer 
and washed to remove any remaining organ stroma. Cells 
were washed and stained with a fixable viability dye (Ther-
moFisher Scientific) for 30 min at 4°C. Surface staining 
was performed using antibodies for the following markers: 
CD3 (145–2 C11), CD4 (RM4-5), CD8 (53–6.7), CD45 
(30- F11), CD49b (DX5), CD64 (X54-5/7.1), CD19 (ID3) 
from BD Biosciences; CD11c (N418), CD11b (M1/70), 
MHC- II (M114.15.2), XCR-1 (ZET), CXCR3 (CXCR3-
173) from Biolegend and CD103 (2E7) from Ther-
moFisher Scientific. For intracellular staining, cells were 
fixed and permeabilized using the Foxp3 staining buffer 
(ThermoFisher Scientific), following manufacturer’s 
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instructions. Samples were stained with Ki67 (SOLA15) 
and B- cell lymphoma-2 (Bcl-2) (3F11) from BD Biosci-
ences; Foxp3 (FJK- 16s) and IRF8 (V3GYWCH) from 
ThermoFisher Scientific; GzmB (GB11) and CXCL9 
(MIG- 2F5.5) from Biolegend; and X- C Motif Chemo-
kine Ligand 1 (XCL1) (BAF486) from R&D Systems 
followed by PE- Streptavidin (BD Biosciences). Cells were 
acquired in a Fortessa flow cytometer (BD Biosciences). 
Data analysis was performed using FlowJo software (Tree 
Star, Ashland, Oregon, USA). Analyses of tumor immune 
infiltrates were performed in two to three independent 
experiments for each type of tumor.
In vitro stimulation of tILs
Tumor cell suspensions were seeded in 24- well plates 
in the presence of beads conjugated with α-CD3/CD28 
antibodies (Dynabeads Mouse T Activator CD3/CD28, 
11 452D, ThermoFisher Scientific) and incubated at 
37°C in the presence of anti- CD107a antibody (1D4B, BD 
Biosciences) and monensin (GolgiStop, BD Biosciences). 
Similar cultures without antibody- stimulation were used 
as negative controls. After 6 hours of incubation, cells 
were harvested and stained for surface markers and intra-
cellular IFN-γ (XMG1.2, BD Biosciences).
Immunohistochemistry
Immunohistochemistry (IHC) was performed as previ-
ously reported.52 After deparaffinization, 4.5 µm thick 
sections were incubated with rabbit anti- CD3 (SP7, Abcam, 
ab16669, 1:100), followed by treatment with tyramide- 
fluorophore reagent (PerkinElmer, NEL791001KT; 
Life Technologies, T20950) at 1:100 dilution in Ampli-
fication plus buffer (PerkinElmer, NEL791001KT) for 
10 min at room temperature (RT) and washed in Tris- 
Buffered Saline, 0.1% Tween®20 Detergent (TBS- T) 
and H20. Similar procedure was performed for the rat 
anti- CD8 (4SM15, ThermoFisher, 14-0808-82, 1:2000), 
rat anti- CD4 (4SM95, ThermoFisher, 14–9766, 1:200) 
and rat anti- Foxp3 antibodies (FJK- 16s, ThermoFisher, 
145 773–82, 1:100) using an anti- rat secondary HRP 
(Vector Labs, MP-7444–15). After washes in TBS- T, 
4′,6- diamidino-2- phenylindole (DAPI) (Life Technol-
ogies, D1306, 1 mg/mL stock, 1:500 in Phosphate buff-
ered saline (PBS)) was added to slides for 10 min at RT. 
Slides were imaged at both 4 x, and 20 x using Vectra 
imaging software (PerkinElmer), and the number of cells 
were enumerated from the top nine hotspots images, to 
provide equal weighting for each mouse, using inForm 
analysis software (PerkinElmer).
Analysis of cytokine and chemokine levels in tumor lysates
Excised tumors were resuspended in T- Per Tissue Protein 
Extraction Reagent (ThermoFisher Scientific) and 
homogenized using 2.8 mm ceramic (zirconium oxide) 
beads (Precellys Lysing kit) and Precellys Evolution 
Homogenizer. Tumor lysates were recovered after spin at 
13 000 rpm for 15 min at 4°C and analyzed for cytokine 
levels using U- PLEX Biomarker group 1 mouse Assay (35 
analytes; Meso Scale Diagnostics) and ELISAs specific for 
the mouse chemokines XCL1 (ThermoFisher Scientific) 
and CXCL9 (ThermoFisher Scientific), following manu-
facturers instructions.
gene expression analysis by nCounter PanCancer immune 
profiling panel
Tumors were mechanically disrupted in RLT buffer 
(QIAGEN) using 2.8 mm ceramic beads (Precellys 
Lysing kit) and Precellys Evolution Homogenizer. RNA 
extraction was performed with RNeasy (QIAGEN) 
including on- column DNase I digestion, according to 
the manufacturer’s instructions. nCounter PanCancer 
Immune Profiling Panel (NanoString Technologies) was 
used to monitor the expression of a panel of 780 genes 
related to immuno- oncology. The mRNA molecules were 
counted with the NanoString nCounter at the Labora-
tory of Molecular Technology (Advanced Technology 
Program, Frederick National Laboratory). Analysis was 
performed with a workflow written in R and through 
a user interface developed on the Foundry Platform 
(Palantir Technologies). Raw data were filtered to remove 
low expressed genes, leaving 758 genes out of the original 
780. To normalize data, log transformation and quan-
tile normalization were applied. To define differentially 
expressed genes, we run limma53 and set thresholds at 
two- fold change and p<0.05 difference between groups 
(adjusted p value following Bonferroni multiple compar-
ison testing). Gene enrichment analysis on the Gene 
Ontology (GO) database was subsequently performed on 
the top 150 genes (sorted by t- statistic) using the Fisher’s 
exact test (https:// github. com/ CCBR/ l2p). Heatmaps 
were represented as Z- score centered and rescaled. To 
determine immune cell scores, the geometric mean of 
the cell marker genes were calculated from normalized 
gene expression values within each sample. Cell type gene 
markers for cytotoxic cells and DCs were determined as in 
Danaher et al.54
statistics
Differences between untreated and hetIL-15 treated 
mice were evaluated by a two- tailed Mann- Whitney U 
test. Tumor areas were plotted as mean±standard error of 
the mean (SEM) for each data point, and tumor growth 
curves were compared using mixed- effects analysis of vari-
ance (ANOVA). The p values were corrected for multiple 
comparisons using Holm- Sidak test. Prism V.8.1 software 
package was used for analysis.
resuLts
hetIL-15 induces intratumoral accumulation of Cd8+ t and nk 
cells resulting in control of tumor growth
To address the role of endogenous IL-15 in tumor 
growth, MC38 colon carcinoma cells were administered 
SC to C57BL/6 wild type (wt) and age- matched IL-15 
KO mice, and tumor development was monitored over-
time. Tumors showed an accelerated growth in mice 
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Figure 1 hetIL-15 delays tumor growth and promotes tumor- infiltrating lymphocytes proliferation and survival. Mice, implanted 
with 2×105 MC38 cells at day −5, were randomized in two different treatment groups: hetIL-15 (blue traingle) and PBS (gray 
square) administration. hetIL-15 (3 µg/injection/mouse) was injected IP three times per week. (A) Control mice (n=10) and 
hetIL-15- treated mice (n=9) received eight injections, starting at day 0, and tumor growth was monitored overtime. Tumor size 
measurements were performed every 2 to 3 days. Tumor area (length×width) mean±SEM for each time point are shown. Similar 
results were obtained in three independent experiments. (B–G) MC38 tumor- bearing mice were sacrificed at day eight after 
treatment with either PBS or hetIL-15 (1 day after the fourth administration). Tumor immune infiltrates were analyzed by flow 
cytometry to determine: (B) frequency of tumor- infiltrating CD8+ T cells. Data of three independent experiments were combined; 
(C) percentage of dividing tumor infiltrating CD8+T cells; (D) expression of the survival factor Bcl-2 in the tumor- infiltrating 
CD8+ T cell population; (E) frequency of tumor- infiltrating NK cells; (F) percentage of dividing tumor infiltrating NK cells; (G) 
intratumoral CD8+ T cells/Treg ratio for each treatment group. Bars represent mean±SEM. P values are from Mann- Whitney 
U test. hetIL-15, heterodimeric interleukin-15; IP, intraperitoneal; MFI, mean fluorescence intensity; NK, natural killer; SEM, 
Standard error of the mean.
lacking IL-15 compared with wt mice (online supplemen-
tary figure 1), suggesting that IL-15- dependent immune 
mechanisms can limit the development of tumors. We 
next used human cell- produced hetIL-15 treatment as 
an anticancer immunotherapeutic drug in the MC38 
colon carcinoma mouse model. hetIL-15 administration, 
following a 2- week schedule with three injections/week 
and a dose of 3 µg/injection by IP delivery, resulted in a 
significant delay of tumor growth (figure 1A). Analysis of 
the tumor immune infiltrate from untreated and hetIL-15 
(day 8, 1 day after the fourth administration) treated mice 
was performed by both flow cytometry (figure 1B–G) 
and IHC (figure 2). hetIL-15 treatment increased the 
number of intratumoral CD8+ T cells by ~3 x (figure 1B). 
The proliferation rate of intratumoral CD8+ T cells in 
untreated mice was ~50%–60%, suggesting rapid lympho-
cyte turnover in tumor sites. On hetIL-15 treatment, the 
percentage of Ki67+ CD8+ T cells significantly increased 
to ~80% (figure 1C). Tumor- infiltrating CD8+ T cells were 
also characterized by a significant upregulation in the 
expression of Bcl-2 in comparison to control mice, indica-
tive of increased survival (figure 1D). Similar results were 
also observed in the NK cells analyzed in MC38- bearing 
mice (figure 1E–F). hetIL-15 treatment promoted a ~3 
x increased accumulation of NK cells in the tumor sites 
(figure 1E) and these NK cells showed significantly 
higher proliferation rate in comparison to control mice 
(figure 1F).
Favorable outcome in cancer immunotherapy treat-
ments has also been linked to the ratio of CD8+ T cells 
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Figure 2 CD8+ T cells accumulation and increased CD8+/Treg ratio in MC38 tumors from mice treated with hetIL-15. (A) 
Immunohistochemistry staining of MC38 tumor sections from control (left panel) and hetIL-15- treated mice (right panel). 
Analysis was performed at day eight after treatment with either PBS or hetIL-15 (1 day after the fourth administration). TILs 
were monitored with CD3 (orange), CD4+ (red), CD8+ (yellow) and FOXP3 (green) antibodies. A representative image (×20 
magnification) from one mouse/group is shown. Insert represents a ×4 magnification. (B–D) The number of CD8+ T cells per 
mm2 (B), the number of Tregs per mm2 (C), and the ratio of CD8+ T cells/Treg cells (D). Data are from nine ×20 ‘hotspot’ fields 
(containing the highest number of CD8+ T cells/mm2) per mouse. Six mice in each treatment group were analyzed. P values are 
from Mann- Whitney U test. hetIL-15, heterodimeric interleukin-15; TILs, tumor- infiltrating lymphocytes.
to Tregs.8 For this reason, we determined the CD8+/Treg 
ratio within the tumors from untreated and hetIL-15 
treated mice. As previously reported in the B16 mela-
noma model,47 MC38 tumors were characterized by a 
significant infiltration of Treg cells with a CD8+/Treg 
ratio of ~2. hetIL-15 promoted a significant accumulation 
of intratumoral CD8+ T cells resulting in a ~5 x increase in 
the CD8+/Treg ratio (figure 1G).
The lymphocyte infiltrate in MC38 tumors was also 
analyzed by IHC (figure 2). Staining of tumor sections 
with antibodies against CD3, CD4, CD8 and Foxp3 
confirmed that the lymphocytes isolated on in vitro diges-
tion were of intratumoral origin rather than peripherally 
associated with the excised tumors (figure 2A). Quantifi-
cation of CD8+ T cells/mm2 (figure 2B) by IHC showed 
a significant increase in the hetIL-15 group, with lympho-
cytes distributed throughout the tumor. In contrast, 
hetIL-15 treatment did not affect the number of tumor- 
infiltrating Tregs (figure 2C). As a consequence of CD8+ 
T cell expansion, a significant increase in the CD8+ T 
cells/Treg ratio was also observed by IHC on hetIL-15 
administration (figure 2D).
The anticancer efficacy of hetIL-15 was verified in the 
mouse TC-1 carcinoma model using the same methods 
(online supplementary figure 2A). hetIL-15 treatment 
was associated with significantly increased intratumoral 
CD8+ T cells, unchanged frequency of tumor infiltrating 
Tregs and increased CD8+/Treg ratio (online supplemen-
tary figure 2B–F).
The systemic effects of hetIL-15 treatment were evalu-
ated in MC38- bearing mice. hetIL-15 induced a significant 
increase in the absolute number of CD8+ T and NK cells 
in spleen (online supplementary figure 3A–D, respec-
tively) with a significant upregulation in the expression 
of Ki67+ cells (online supplementary figure 3B–E, respec-
tively) and the survival marker Bcl-2 (online supplemen-
tary figure 3C).
Taken together, these data show that hetIL-15 sustains 
proliferation and survival of lymphocytes both in tumor 
and spleen, and verify the efficacy of hetIL-15 as anti-
cancer immunotherapeutic agent.
hetIL-15 induces t cells with an effector-like gene signature 
and promotes their cytotoxic functions
We performed gene expression analysis of MC38 tumors 
using a panel of 780 immune- oncology related gene 
probes (Nanostring Technology). Tumors were excised 
3 hours after the fourth hetIL-15 administration and 
processed for mRNA isolation. Comparison of gene 
expression identified several significantly overexpressed 
genes in tumors recovered from hetIL-15- treated mice 
(figure 3A). Gzmb and Gzma were the most upregulated 
genes (~5 x, adjusted p<0.01). Xcl1, Prf1, Ctsw, CD69, 
Klrc1, Ncr1 and Fasl were also significantly overexpressed 
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Figure 3 Tumors from hetIL-15- treated mice comprise lymphocytes with an effector- like gene signature and enhanced 
cytotoxic functions. (A) Gene expression analysis from MC38 tumors recovered from mice treated with either PBS (n=5) or 
hetIL-15 (n=6) was performed by the Nanostring technology using a panel of 780 immune- oncology related gene probes. 
The analysis was conducted at 3 hours after the fourth administration. Volcano plot depicts differentially expressed genes 
between the two treatment groups, highlighting the upregulated genes (blue dots) on hetIL-15 treatment. To define differentially 
expressed genes, we used one log2 change (vertical dotted lines) and p<0.05 (adjusted p value for multiple comparison; 
horizontal broken line) difference between groups. (B–D) Tumor- resident CD8+ T cells (B), CD4+ T cells (C) and NK cells (D) were 
analyzed for the expression of the cytotoxic marker GzmB by intracellular staining followed by flow cytometry. Dot plots from a 
representative animal (upper panels) and the percentage of GzmB+ cells within each cell subset (bottom panel) are shown. (E) 
Pie charts show the proportion of GzmB+Ki67-(red), GzmB+Ki67+(black), GzmB-Ki67+(gray) and GzmB-Ki67-(white) cells within 
the total CD8+ T cell subset in tumor (left panel) and spleen (right panel) of hetIL-15 treated animals. (F–G) IFN-γ production and 
degranulation (CD107) in tumor- infiltrating CD8+ T cells (F) and CD4+ T cells (G) on ex vivo stimulation with beads coated with 
anti- CD3/CD28 antibodies. Dot plots show a representative animal from each group. Bars represent mean±SEM. P values are 
from Mann- Whitney U test. hetIL-15, heterodimeric interleukin-15; IFN-γ, interferon-γ; NK, natural killer; GzmB, Granzyme B; 
SEM, Standard error of the mean.
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Figure 4 hetIL-15 enhances the production of XCL1 
by tumor resident CD8+ T and NK cells. (A) Heatmap, 
represented as Z- score centered and rescaled, of the 
genes included in the GO:0002548 monocyte migration and 
chemotaxis pathway from control (n=5) and hetIL-15- treated 
(n=6) MC38- bearing mice. Significantly upregulated genes 
in hetIL-15- treated mice in comparison to control mice are 
depicted. (B) Evaluation of the chemokine XCL1 in MC38 
tumors. The panel shows the tumor mRNA counts for Xcl1 
as determined by the Nanostring technologies in both PBS 
treated (n=5) and hetIL-15- treated (n=6) MC38- bearing mice. 
(C) MC38 tumor lysates from either PBS- treated (n=11) 
or hetIL-15- treated (n=10) mice were assessed for XCL1 
concentration by ELISA. (D) Flow cytometric analysis of XCL1 
production by NK and CD8+ T cells. Histogram overlays 
show the expression of XCL1 by intratumoral NK and CD8+ 
T cells from a representative hetIL-15 (blue) and PBS (black) 
treated mouse. Solid gray histogram shows non- staining 
control. The XCL1 geometric mean fluorescent intensity 
(MFI) in the tumor- infiltrating NK and CD8+ T cells from each 
therapeutic group (n=6) are shown in the right panel. Bars 
represent mean±SEM. P values are from Mann- Whitney U 
test. hetIL-15, heterodimeric interleukin-15; NK, natural killer; 
SEM, Standard error of the mean.
in hetIL-15- treated mice (figure 3A). These upregulated 
genes after hetIL-15 treatment represent an expression 
signature that corresponds to activated TILs with cyto-
toxic phenotype. Nanostring analysis also identified addi-
tional functional pathway signatures, including signal 
transducer and activator of transcription intracellular 
signaling, T- cell receptor (TCR) recognition of cognate 
antigen, IFNs signaling, increased metabolic rate and 
immune cell chemotaxis (online supplementary figure 
4).
To confirm the transcriptomic data, we analyzed 
the GzmB content of TILs. Flow cytometric analysis 
demonstrated that provision of hetIL-15 resulted in 
higher proportion of tumor- infiltrating CD8+ and CD4+ 
T lymphocytes, as well as NK cells harboring GzmB in 
comparison to untreated mice (figure 3B–D, respec-
tively). Thus, hetIL-15 treatment led to a significant 
accumulation of GzmB+ CD8+, CD4+ T and NK cells 
per tumor. Similar results were obtained in the TC-1 
tumor model (online supplementary figure 2G). We also 
analyzed the GzmB content of splenic CD8+ T and NK 
cells. In untreated animals, both CD8+ T and NK cells 
were negative for GzmB, but on hetIL-15 administra-
tion, we observed a significant increase in the frequency 
of lymphocytes harboring GzmB (online supplementary 
figure 3F and G, respectively). Interestingly, we iden-
tified an intratumoral CD8+ T cell subset characterized 
by the expression of GzmB and lack of Ki67 (figure 3E, 
red) in hetIL-15 treated mice, but these cells were almost 
completely absent within the spleen. These GzmB+Ki67- 
CD8+ T cells are indicative of a terminally differentiated 
cytotoxic phenotype and represented ~15% of the total 
CD8+ T cells within the tumors (figure 3E). These data 
indicate that hetIL-15 treatment preferentially induces 
intratumoral accumulation of CD8+ T cells committed to 
killing.
We also investigated the production of IFN-γ and 
the degranulation activity (CD107+) by MC38 tumor- 
derived T cells on ex vivo stimulation with beads coated 
with α-CD3/CD28 antibodies. We found that ~10% of 
CD8+ (figure 3F) and ~5% of CD4+ (figure 3G) tumor- 
infiltrating T cells were able to secrete IFN-γ in untreated 
control mice. Significant increase in the frequency of 
IFN-γ+ CD8+ (~20%) and CD4+ (~10%) T cells was found 
in tumors from the hetIL-15- treated group, suggesting 
that hetIL-15 increases the production of IFN-γ within 
the tumor. Similarly, we found an increased frequency of 
degranulating CD107a+ CD8+ T cells in hetIL-15- treated 
in comparison to control mice (figure 3F).
Overall, hetIL-15 administration shapes the tumor 
microenvironment towards a Th1 profile, promoting acti-
vation and cytotoxic functional commitment in tumor- 
resident T and NK cells.
cdC1 accumulate in tumors of hetIL-15 treated mice
Differential gene expression analysis showed that, in 
addition to pathways related to NK and T cell activation 
(online supplementary figure 4), hetIL-15 treatment 
upregulated several intratumoral chemokines stimu-
lating pathways related to myeloid cell migration and 
chemotaxis (figure 4A, GO:0002548, p=0.039). Gene 
expression analysis of the whole tumor revealed a ~4 x 
increase in the expression of XCL1 mRNA on hetIL-15 
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administration (figure 4B). Analysis of XCL1 protein 
within the tumor was performed by ELISA at 6 hours 
after hetIL-15 IP administration. A ~3 x increase in 
XCL1 concentration was detected in tumor extracts from 
hetIL-15 treated mice compared with tumors from PBS 
treated mice (figure 4C). To identify the source of XCL1, 
cell suspensions from MC38 tumors were analyzed for the 
chemokine production in vivo. On day 8 after initiation 
of treatment, mice received an IT injection of brefeldin 
to block protein secretion in vivo. Tumors were excised 
and isolated cells were analyzed by flow cytometry using 
a panel of antibodies for the detection of NK and T cells 
as well as XCL1. We found that both tumor- infiltrating 
NK and CD8+ T cells produce XCL1 (figure 4D). hetIL-15 
treatment resulted in a significant increase of XCL1 
production by both cell subsets, as suggested by increased 
XCL1 mean fluorescence intensity.
XCL1 has been linked to the tumor recruitment of 
cDC1.11 16 55–57 These cells are known to support anti-
tumor responses through the attraction, stimulation 
and expansion of tumor- specific CD8+ T cells.58 For 
this reason, we evaluated the myeloid cell infiltrate in 
MC38 tumors on hetIL-15 treatment. A previously estab-
lished flow cytometry protocol allows the distinction 
between cDC1, defined as CD45+MHCIIhighCD64-CD-
11c+CD11bdim, and other myeloid populations including 
CD64+ macrophages and CD11bhigh conventional type 2 
DC (cDC2).13 59 Additionally, expression of CD103, XCR1 
and IRF8 on cDC1 has been linked to their ability to 
cross- present antigens and stimulate efficient CD8+ T cell 
responses.14–16 55 The strategy outlined in figure 5A was 
used to identify cDC1 expressing XCR1, CD103 and IRF8 
within CD45+ immune cells infiltrating the tumors. cDC1 
constitute approximately 0.1% of intratumoral CD45+ 
leucocytes in MC38 tumors, in agreement with a previous 
report.10 The expression of CD64 on these cells was ~4 x 
reduced in comparison to MHCII+CD11b+ myeloid cells 
(online supplementary figure 5A). Tumor- infiltrating B 
cells represented between 0.05% and 0.6% of CD45+M-
HCII+ and did not stain positive for CD11c, XCR1 and 
IRF8 (online supplementary figure 5B–D).
Treatment with hetIL-15 resulted in significantly 
increased accumulation of cDC1 expressing CD103+X-
CR1+IRF8+ in MC38 tumors (figure 5B, left panel). Expres-
sion of the XCL1 receptor (XCR1) on this cell subset 
suggests its ability to migrate toward the XCL1 gradient 
within the tumors stimulated by hetIL-15 treatment. 
Analysis of tumor- infiltrating cDC1 was also performed 
in control and hetIL-15- treated mice bearing TC-1 carci-
noma. Similarly, hetIL-15 treatment was associated with 
~2 x increase in the number of cDC1 expressing CD103, 
XCR1 and IRF8 localized within the tumors (figure 5B, 
right panel). These results are in agreement with the 
gene expression data revealed by transcriptomics (Nanos-
tring Technology). Based on the differential expression 
of cell type specific genes, cell scores were calculated for 
different immune cell subsets as described in Material 
and Methods. hetIL-15 treatment induced changes in the 
composition of the tumor immune infiltrate (figure 5C). 
hetIL-15 therapy was associated with a significant upreg-
ulation of the gene expression profile of both cytotoxic 
cells (figure 5D) and DCs (figure 5E). In contrast to the 
results obtained within the tumors, we observed a reduc-
tion in the frequency of XCR1+CD103+IRF8+ cDC1 in 
the spleens of hetIL-15 treated animals compared with 
control mice (online supplementary figure 3H).
Taken together, these data indicate that hetIL-15 treat-
ment promotes the production of the chemokine XCL1 
by intratumoral lymphocytes leading to increased tumor 
infiltration by CD103+XCR1+IRF8+ cDC1.
hetIL-15 treatment stimulates CXCL9 and CXCL10 secretion by 
intratumoral myeloid cells attracting CXCr3+ effector t cells 
by an IFn-γ dependent way
The intratumoral accumulation of cDC1 and cytotoxic 
lymphocytes promoted by hetIL-15 was accompanied 
by increased IFN-γ production by T cells (figure 3) 
resulting in higher IFN-γ concentration as measured in 
tumor lysates by Meso Scale Discovery (MSD) quantita-
tion (figure 6A). Differential gene expression analysis 
showed an increase in IFN-γ mRNA (figure 6B) and 
IFN-γ responsive genes and confirmed the enrichment 
of this pathway within the tumor in hetIL-15 treated 
animals (GO:0034341, p=0.049; figure 6B). The IFN-γ-de-
pendent chemokines CXCL9 and CXCL10 were also 
assessed in tumor lysates obtained from MC38 bearing- wt 
and IFN-γ KO mice. Before hetIL-15 treatment, CXCL9 
tumor concentration was slightly lower in IFN-γ KO 
mice compared with wt mice, although this difference 
did not reach statistical significance by one- way ANOVA 
(figure 6C, left panel). CXCL10 levels were similar in 
both strains of mice (figure 6C, right panel). hetIL-15 
administration resulted in a ~3 x increase in the intratu-
moral concentration of both CXCL9 and CXCL10 only 
in wt mice, with no changes being observed in IFN-γ KO 
animals (figure 6C). To dissect the mechanism of intra-
tumoral chemokine production in response to hetIL-15, 
MC38- bearing wt and IFN-γ KO mice were treated with 
brefeldin delivered IT to block protein secretion in vivo. 
CXCL9 production in the excised tumors was analyzed 
by flow cytometry using a mixture of antibodies targeting 
both T and myeloid cells. We found that all tumor- 
associated myeloid cell subsets analyzed (macrophages, 
monocyte- derived DC and cDC1) produce CXCL9 in vivo 
(figure 6D). hetIL-15 administration increased signifi-
cantly the frequency of myeloid cells staining positive 
for CXCL9 in wt mice (figure 6D). cDC1 were one of the 
sources of CXCL9 (~8% and~2% in wt and IFN-γ KO mice, 
respectively). The frequency of cDC1 cells producing 
CXCL9 increased to ~25% in wt mice, but no changes 
were observed in IFN-γ KO mice (figure 6E), indicating 
that IL-15- stimulated CXCL9 production is IFN-γ-depen-
dent. To confirm these data, single cell suspensions of 
MC38 tumors were cultured for 6 hours in the presence 
of either hetIL-15 or recombinant IFN-γ. Flow cytometry 
analysis showed that cDC1 produced CXCL9 in response 
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Figure 5 hetIL-15 treatment results in recruitment of XCR1+CD103+IRF8+ cDC1 into tumors. (A) Gating strategy for the 
characterization of cDC1. (B) The frequency of tumor- infiltrating CD103+XCR1+IRF8+ cDC1 was determined in MC38 (left panel) 
and TC-1 tumors (right panel) recovered from hetIL-15 or PBS- treated control mice. The number of CD103+XCR1+IRF8+ cDC1 
cells in each tumor was normalized per million of cells present in the tumor suspension. The values from individual animals and 
mean±SEM are shown. (C) Heatmap representing the immune cell composition of tumors on hetIL-15 treatment. Cell scores 
were calculated for different immune cell subsets as described in material and methods. (D–E) RNA cell score for cytotoxic 
cells (D) and dendritic cells (E) was calculated for tumors recovered from control (gray, n=5) and hetIL-15 (blue, n=6) treated 
mice using Nanostring measurements as described in material and methods. Individuals animals and mean±SEM are shown. P 
values are from Mann- Whitney U test. cDC1, conventional type 1 dendritic cells; hetIL-15, heterodimeric interleukin-15; SEM, 
Standard error of the mean.
to hetIL-15 only from wt mice(figure 6F). As expected, 
stimulation with recombinant IFN-γ restored the ability of 
cDC1 from IFN-γ KO mice to produce CXCL9 to similar 
levels observed in wt mice (figure 6F). These results are 
in agreement with the measurements of intratumoral 
chemokine levels and demonstrate that hetIL-15 stimu-
lation of CXCL9 and CXCL10 production is, at least in 
part, IFN-γ dependent.
CXCL9 and CXCL10 are key regulators of leucocyte 
trafficking.60 Effector CD8+ T cells and a subset of NK cells 
expresses CXCR3, the receptor for CXCL9, CXCL10 and 
CXCL11, and they migrate following gradients of these 
chemokines.13 23 61 We observed an increased presence of 
CD8+ T lymphocytes and NK cells expressing CXCR3 in 
blood of hetIL-15 treated wt mice (figure 6G). Evaluation 
of CXCR3 expression in TILs was not possible, due to the 
use of collagenase necessary for tumor processing. Overall, 
these data support a mechanism of hetIL-15 action in 
which lymphocyte trafficking to the tumor is controlled 
by a gradient of the chemokines CXCL9 and CXCL10. 
10 Bergamaschi C, et al. J Immunother Cancer 2020;8:e000599. doi:10.1136/jitc-2020-000599
Open access 
Figure 6 hetIL-15 treatment stimulates secretion of CXCL9 and CXCL10 from tumor- localized myeloid cells in an IFN-γ 
dependent fashion. (A) Intratumoral IFN-γ concentration measured by U- PLEX MSD in MC38 tumors excised from mice treated 
with PBS (gray square; n=12) or hetIL-15 (blue triangle; n=12). (B) Heatmap for the genes included in the GO:0034341 IFN-γ 
related pathway from control (n=5) and hetIL-15- treated (n=6) MC38- bearing mice. Heatmap is represented as Z- score centered 
and rescaled. Significantly upregulated genes in hetIL-15- treated vs control mice are depicted. (C) Tumor concentration of 
CXCL9 (left panel) and CXCL10 (right panel) in PBS- (gray squares) or hetIL-15- treated (blue triangles) wt and IFN-γ KO mice. 
Bars represent mean±SEM. Data from one of two representative experiments are shown. (D) Dot plots showing the in vivo 
production of CXCL9 by tumor- associated macrophages (defined as MHCII+CD64+ cells), monocyte- derived dendritic cells 
(defined as MHCII+CD64-CD11c+CD11bhigh) and cDC1, treated with either PBS (upper panels) or hetIL-15 (lower panels). (E) 
The frequency of intratumoral cDC1 cells producing CXCL9 is reported as the percentage of the total cDC1 in wt and IFN-γ KO 
mice treated with PBS (gray square) or hetIL-15 (blue triangle). Bars represent mean±SEM from one representative experiment. 
(F) CXCL9 production by intratumoral cDC1 recovered from MC38 tumor- bearing wt and IFN-γ KO mice. Cells were stimulated 
ex vivo with hetIL-15 or IFN-γ and the ability to produce CXCL9 by cDC1 was evaluated by flow cytometry. Bars represent 
mean±SEM. (G) The frequency of CXCR3+ CD8+ T cells and NK cells in blood of MC38- bearing mice treated with PBS (gray 
square) or hetIL-15 (blue triangles) are shown as the percentage of the parental population. Bars represent mean±SEM. P 
values are from Mann- Whitney U test. cDC1, conventional type 1 dendritic cells; hetIL-15, heterodimeric interleukin-15; IFN-γ, 
interferon-γ; wt: wild type; KO, knock out; NK, natural killer; SEM, Standard error of the mean.
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Figure 7 Model representing the hetIL-15 triggered pathway 
for tumor infiltration by lymphocytes and dendritic cells. 
Activated CD8+ T and NK cells release IFN-γ and XCL1 
in response to hetIL-15 treatment. The increased XCL1 
concentration recruits cross- presenting cDC1 expressing 
the chemokine receptor XCR1. cDC1 in tumors respond to 
hetIL-15 by secreting the chemokines CXCL9 and CXCL10, 
in an IFN-γ dependent manner. Systemic effects of hetIL-15 
includes the enhanced frequency of circulating CXCR3+ 
CD8+ T and NK cells that can further infiltrate the tumor, 
following the CXCL9 and CXCL10 chemokine gradient. cDC1, 
conventional type 1 dendritic cells; hetIL-15, heterodimeric 
interleukin-15; IFN-γ, interferon-γ; NK, natural killer.
Myeloid cells, including macrophages, monocyte- derived 
DC and cDC1 are among the sources of these chemoat-
tractants in the tumor in an IFN-γ dependent fashion. 
Hence, the antitumor effects of hetIL-15 treatment are 
linked to the increase of intratumoral lymphocyte infiltra-
tion by an IFN-γ-dependent mechanism.
dIsCussIon
In this study, using the MC38 colon and TC-1 epithe-
lial carcinoma mouse models, we demonstrate that 
hetIL-15 orchestrates a multipronged immune response 
that includes leucocyte expansion and trafficking to the 
tumor, lymphoid- myeloid cell interactions and enhanced 
cytotoxic responses through the induction of a favor-
able cytokine milieu that includes increased intratu-
moral production of specific chemokines. The increased 
tumor accumulation of CD8+ T and NK cells observed 
in hetIL-15 treated animals is the result of multiple and 
concomitant effects, combining both expansion of tumor- 
resident lymphocytes and recruitment of new immune 
cells via chemokine gradients. hetIL-15 effects are both 
direct and indirect and result in control of tumor growth. 
hetIL-15 directly affects NK, CD8+ and CD4+ T cells within 
the tumor promoting their proliferation, survival and 
cytotoxic commitment, with high levels of IFN-γ produc-
tion and upregulation of GzmA, GzmB and perforin. 
Activated lymphocytes also secrete XCL1 in response to 
hetIL-15 treatment, a chemokine likely responsible for 
the enhanced intratumoral influx of cDC1 detected in 
hetIL-15- treated animals. cDC1, together with macro-
phages and monocyte- derived DC, are one of the sources 
of the chemokines CXCL9 and CXCL10, previously 
reported to direct trafficking of CXCR3+ effector lympho-
cytes to tumor sites.13 23 Importantly, CXCL9 and CXCL10 
secretion by myeloid cells is not constitutive and requires 
exposure to IFN-γ, suggesting a positive feedback loop 
whereby the hetIL-15- dependent increase in intratumoral 
XCL-1 and IFN-γ–producing lymphocytes enhances cDC1 
recruitment and amplifies the CXCL9/10- directed intra-
tumoral infiltration by CXCR3+ effector lymphocytes, as 
summarized in the model depicted in figure 7.
The intratumoral leucocyte and cytokine composi-
tion orchestrates local interactions that result in either 
enhancing or inhibiting antitumor immunity. A high 
number of tumor- infiltrating effector lymphocytes is 
considered to be the most predictive biomarker for cancer 
immunotherapy success.3 Effective immunotherapeutic 
agents must promote an immune landscape capable of 
recruiting T and NK cells within the tumor and enhance 
their antitumor functions. In our study, tumors had an 
accelerated growth in IL-15 KO mice, that lack NK cells 
and have diminished memory CD8+ T cells, compared 
with wt mice. Moreover, administration of hetIL-15 
resulted in control of tumor growth in two different 
cancer models in C57BL/6 mice. hetIL-15 therapy stimu-
lated trafficking of CD8+ T and NK cells into the tumors, 
and promoted proliferation (elevated Ki67 levels) and 
survival (elevated Bcl-2) of the intratumoral lymphocytes. 
TILs in hetIL-15- treated tumors were also characterized 
by a gene expression pattern and phenotype of activated 
cytotoxic lymphocytes. An important component of the 
hetIL-15 mediated anti- tumor effects in our study was the 
increased TILs and CD8+/Treg ratio in both MC38 and 
TC-1 tumors, suggesting that hetIL-15 may be a favorable 
immunotherapeutic intervention in tumors dependent 
on Tregs- suppressive functions. Taken together, our data 
suggest that the recruitment and activity of CD8+ T and 
NK cells within the tumor are responsible for the potent 
anticancer property of hetIL-15 therapy. These data are 
in agreement with a recent study demonstrating that 
endogenous soluble hetIL-15 is expressed in the tumor 
niche and regulates the frequency of TILs.25 26
Using ‘omics’ approaches (Nanostring RNA analysis, and 
Mesoscale in addition to the ELISA protein measurements), 
we identified mechanisms responsible for the homing of 
immune cells to the tumor niche in response to hetIL-15 
therapy. hetIL-15 upregulated intratumoral Xcl1 mRNA 
expression, and tumor lysates from hetIL-15 treated mice 
were enriched in XCL1 chemokine. Immunophenotyping 
analysis of intratumoral lymphocytes revealed activated 
CD8+ T and NK cells as the source of this chemokine, in 
agreement with previous reports.11 62 63 XCL1 increase asso-
ciated with higher number of CD103+XCR1+IRF8+ cDC1. 
XCL1 is often cosecreted with IFN-γ, CCL3, CCL4 and 
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CCL5 by CD8+ T and NK cells and has emerged as a critical 
component of the Th1 immune response against several 
infections.64 Dorner et al16 showed that XCL1 is a selective 
chemoattractant for murine splenic DCs highly efficient 
in cross presentation. A recent report showed that cDC1 
accumulation in transplantable mouse tumors depends 
on tumor- infiltrating NK cells secreting the chemoattrac-
tants CCL5 and XCL1, whereas disruption of this mech-
anism resulted in cancer immune evasion.11 Additionally, 
in certain human cancers, patient survival correlates with 
the transcript level of CCL5 and XCL1, which were also 
positively associated with the abundance of cDC1- like DCs 
expressing CLEC9A, XCR1, CLNK and BATF3, highlighting 
the clinical relevance of the findings. cDC1 uptake dead 
tumor cells and cross- present tumor- derived peptides to 
naïve CD8+ T cells in the draining lymph nodes, inducing 
primary cytotoxic responses. Additionally, in this work, we 
showed that cDC1 contribute also to the recruitment of 
effector T cells expressing CXCR3, via the secretion of high 
level of CXCL9, in agreement with a previous finding.13
IFN-γ plays a critical role in hetIL-15 mediated anti-
tumor immunity. During hetIL-15 therapy, we observed 
an upregulation of tumor IFN-γ, both mRNA and 
protein, together with enhanced expression of the IFN- 
inducible chemokines CXCL9 and CXCL10. A study 
by Mikucki et al23 highlighted the mandatory role for 
the CXCR3/CXCL9/CXCL10 axis in promoting T cell 
entry into tumors. In agreement with these findings, 
increased levels of CXCL9 and CXCL10 were reported 
to be associated with higher density of tumor CD8+ T 
cells, and to correlate with decreased metastatic burden 
and improved survival in patients with multiple type of 
cancers.65 66 In contrast, CXCL9, CXCL10 and CXCL11 
were poorly expressed in ‘cold’ tumors lacking immune 
infiltrate.67 Spranger et al13 showed that the exclusion of 
CD103+ DCs from the tumor microenvironment lead to 
alteration in the CXCL9/CXCR3 axis and to deficient 
migration of transferred effector T cells to the tumor, 
resulting in immunotherapy resistance in non- inflamed 
tumors. In our study, we reported that cDC1 expressing 
CD103, XCR1 and IRF8 accumulated at higher density 
in hetIL-15 treated tumors. Together with other myeloid 
subsets (macrophages and monocyte- derived DC), 
CD103+XCR1+IRF8+ cDC1 responded to hetIL-15 therapy 
by producing CXCL9 and CXCL10 in an IFN-γ depen-
dent fashion. The increased production of IFN-γ by intra-
tumoral lymphocytes could enhance the intratumoral 
expression of CXCL9 and CXCL10 and subsequent 
recruitment of the hetIL-15- expanded pool of circulating 
CXCR3+ lymphocytes, generating a positive amplification 
loop that limits tumor growth.
A comparative analysis between tumor and spleen allowed 
the identification of hetIL-15 effects restricted to the tumor 
microenvironement. hetIL-15 resulted in an increased 
accumulation of GzmB+Ki67- CD8+ T cells committed to 
killing preferentially in tumors, supporting the hypothesis 
that hetIL-15 acts in conjunction with antigen stimulation. 
Indeed, in a model of adoptive cell transfer, we previously 
reported that hetIL-15 treatment led to enrichment, in an 
antigen- dependent manner, of Pmel-1 cells in B16 tumor 
sites expressing gp100.47 Additionally, we observed a reduc-
tion in the frequency of splenic XCR1+CD103+IRF8+ cDC1 
in hetIL-15 treated animals while their frequency signifi-
cantly increased in tumors. The mechanism responsible for 
this difference is currently under investigation. One possi-
bility is their chemokine- driven mobilization towards tumor 
sites on cytokine treatment.
Preclinical cancer studies support the use of IL-15 to 
promote the development of antitumor responses by 
increasing intratumoral lymphocyte infiltration, favoring 
effector over regulatory cells, and by promoting DC- T cell 
interactions. Several IL-15 formulations are in different 
phases of clinical testing in cancer patients. It has been 
reported that hetIL-15 shows pharmacokinetics and 
bioactivity superior to single chain monomeric IL-15.41 In 
comparison to single chain IL-15, hetIL-15 has a prolonged 
serum half- life and is more bioactive on a molar basis.41 
The superior bioactivity of IL-15 in the heterodimeric 
formulation is mainly the result of the increased stability 
of the heterodimeric protein in vivo. These properties 
allow lower and less frequent dosing, decreasing toxicity. 
Overall, our results show that hetIL-15 administration, by 
changing the cytokine and cellular landscape within the 
tumor, may be a general method to enhance T and cDC1 
cell entry in tumors, increasing the success rate of immu-
notherapeutic interventions.
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